FDA Wants Another Trial for InterMune’s Esbriet NDA

Drug Industry Daily
A A
InterMune has received a complete response letter from the FDA requesting an additional trial for the idiopathic pulmonary fibrosis treatment Esbriet.

To View This Article:

Login

Subscribe To Drug Industry Daily